Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects

Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healt...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Pharmacol
Egile Nagusiak: Green, Justin A, Patel, Apurva K, Patel, Bela R, Hussaini, Azra, Harrell, Emma J, McDonald, Mirna J, Carter, Nick, Mohamed, Khadeeja, Duparc, Stephan, Miller, Ann K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BlackWell Publishing Ltd 2014
Gaiak:
Drug Safety
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283056/
https://ncbi.nlm.nih.gov/pubmed/24700490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.302
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak